<DOC>
	<DOCNO>NCT02944734</DOCNO>
	<brief_summary>The purpose study explore optimal dose fixed-dose combination candesartan cilexetil amlodipine besylate examine safety efficacy combination therapy compare monotherapy patient essential hypertension .</brief_summary>
	<brief_title>Comparison Efficacy Safety Combination Therapy Monotherapy Candesartan Amlodipine Dose-Finding Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Angiotensin II Type 1 Receptor Blockers</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>1 . Male female patient great equal 19 year age 2 . Subject diagnosed essential hypertension administer antihypertensive drug ( Subject may temporarily suspend antihypertensive treatment base doctor 's decision ) 3 . Subject voluntarily agree participate trial sign write informed consent form 1 . Subject severe hypertension ( select arm msSBP ≥ 200 mmHg msDBP ≥ 115 mmHg ) Screening Randomized Trial . 2 . Subject difference blood pressure 20 mmHg SBP 10 mmHg diastolic blood pressure ( DSP ) three consecutive measurement select arm screen visit 3 . Secondary hypertension ( , coarctation aorta , primary hyperaldosteronism , renal artery stenosis , Cushing 's disease , pheochromocytoma , polycystic kidney disease , etc . ) 4 . Symptomatic orthostatic hypotension 5 . Severe heart failure ( New York Heart Association ( NYHA ) Class III/IV ) 6 . Subject acute coronary syndrome ( myocardial infarction unstable angina ) , peripheral vascular disease within past 6 month 7 . History switch another Antiarrhythmic drug ( include electrolyte correction ) , receive Cardioversion ICU treatment within past 6 month 8 . Type 1 diabetes mellitus Uncontrolled Type 2 diabetes mellitus ( HbA1c &gt; 9.0 % ) 9 . Subject Haemodynamic disturbance , heart valve disease structural defect 10 . Severe cerebrovascular disease ( stroke , cerebral infarction , cerebral hemorrhage , etc . within past 6 month ) 11 . Severe eye disease ( retinal hemorrhage , visual impairment , retinal microaneurysm , etc . within past 6 month ) 12 . Autoimmune diseases ( rheumatoid arthritis , systemic lupus erythematosus , etc . ) 13 . Chronic inflammatory disease require continuous antiinflammatory treatment 14 . Clinically significant Renal liver impairment , laboratory abnormality Ccr : 30ml/min Aspartate Aminotransferase ( AST ) Alanine Aminotransferase ( ALT ) &gt; 3 x Upper Limit Normal ( ULN ) 15 . Hypokalaemia ( Serum potassium &lt; 3.5 mmol/L ) hyperkalaemia ( Serum potassium &gt; 5.5 mmol/L ) 16 . Subject gastrointestinal disease ( Crohn 's disease , gastric ulcer , acute chronic pancreatitis ) history gastrointestinal surgery ( include appendectomy hernia surgery ) might significantly alter absorption drug 17. history allergy hypersensitivity Angiotensin II Receptor Blockers ( Candesartan ) Calcium Channel Blocker ( amlodipine ) 18 . Subject heredity defect galactose intolerance , Lapp lactose deficiency , glucosegalactose malabsorption 19 . Subject require concomitant use antihypertensive contraindicate drug ( Tizanidine , dolasetron , Itraconazole , potassium , potassiumsparing diuretic , etc . ) clinical trial 20. history malignant tumor within past 5 year 21. history alcohol drug abuse 22 . Pregnant woman lactate mother 23 . Women plan pregnant 2 month study , woman men use medically acceptable method contraception * * progestin oral implant contraceptive , intrauterine device , condom , partner surgical sterilization , etc . 24 . Use investigational product within past 1 month 25 . Subject judge investigator unsuitable participate study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Candesartan</keyword>
	<keyword>Amlodipine</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Antihypertensive Agents</keyword>
	<keyword>Vasodilator Agents</keyword>
	<keyword>Angiotensin II Type 1 Receptor Blockers</keyword>
	<keyword>Angiotensin Receptor Antagonists</keyword>
	<keyword>Calcium Channel Blockers</keyword>
</DOC>